ClinicalTrials.gov record
Completed Phase 2 Interventional

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

ClinicalTrials.gov ID: NCT00346359

Public ClinicalTrials.gov record NCT00346359. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies

Study identification

NCT ID
NCT00346359
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Fred Hutchinson Cancer Center
Other
Enrollment
40 participants

Conditions and interventions

Interventions

  • allogeneic hematopoietic stem cell transplantation Procedure
  • anti-thymocyte globulin Biological
  • busulfan Drug
  • fludarabine phosphate Drug
  • methotrexate Drug
  • peripheral blood stem cell transplantation Procedure
  • tacrolimus Drug

Procedure · Biological · Drug

Eligibility (public fields only)

Age range
Up to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2006
Primary completion
Not listed
Completion
Oct 31, 2007
Last update posted
May 13, 2010

2006 – 2007

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Fred Hutchinson Cancer Research Center Seattle Washington 98109-1024

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00346359, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 13, 2010 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00346359 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →